首页 > 最新文献

Asian Biomedicine最新文献

英文 中文
2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention. 2024泰国皇家医师学院(RCPT)关于预防动脉粥样硬化性心血管疾病的血脂异常管理临床实践指南。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.2478/abm-2024-0033
Praween Lolekha, Weerapan Khovidhunkit, Chaicharn Deerochanawong, Nuntakorn Thongtang, Thananya Boonyasirinant, Chatchalit Rattarasarn, Aurauma Chutinet, Vuddhidej Ophascharoensuk, Nicha Somlaw, Surapun Sitthisook, Surajit Suntorntham, Wannee Nitiyanant, Rungroj Krittayaphong

Background: The Royal College of Physicians of Thailand (RCPT) published a Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for Atherosclerotic Cardiovascular Disease (ASCVD) Prevention in 2016. The availability of newer classes of medications for dyslipidemia, supported by extensive clinical research findings, indicates a significant need for the updating of the existing clinical practice guideline.

Objectives: To serve as guidelines on the management of dyslipidemia for Thai adults.

Methods: The RCPT Dyslipidemia Guidelines Committee was established with representatives from selected professional societies to revise the 2016 Guideline by critically reviewing the latest evidence. Meetings were conducted from August to December 2023, culminating in a public hearing that engaged various stakeholders in January 2024. The final Thai version received approval in April 2024, while the English translation was completed in October 2024.

Results: Lifestyle modifications and statins remain the cornerstone of therapy for dyslipidemia in adults across various clinical settings. Emerging evidence regarding newer classes of lipid-lowering medications indicates that these treatments are effective in lowering LDL-cholesterol levels and reducing atherosclerotic cardiovascular events. This suggests that they may serve as an add-on therapy for individuals who cannot achieve target levels or who are at high risk for future cardiovascular events. The Thai CV Risk Score is recommended due to its specificity for the Thai population.

Conclusions: The 2024 updated clinical practice guidelines establish a framework, provide recommendations, and serve as a comprehensive resource for the contemporary management of dyslipidemia in adults, with the goal of preventing ASCVD in Thailand.

背景:泰国皇家医师学院(RCPT)于2016年发布了《预防动脉粥样硬化性心血管疾病(ASCVD)的血脂异常药物治疗临床实践指南》。广泛的临床研究结果支持了治疗血脂异常的新药物类别的可用性,这表明迫切需要更新现有的临床实践指南。目的:为泰国成人血脂异常的管理提供指导。方法:成立RCPT血脂异常指南委员会,由选定的专业学会的代表组成,通过批判性地审查最新证据来修订2016年指南。会议于2023年8月至12月举行,最终于2024年1月举行了一场让各利益相关者参与的公开听证会。最终的泰语版本于2024年4月获得批准,而英语翻译则于2024年10月完成。结果:生活方式改变和他汀类药物仍然是各种临床环境中成人血脂异常治疗的基石。关于新型降脂药物的新证据表明,这些治疗方法在降低ldl -胆固醇水平和减少动脉粥样硬化性心血管事件方面是有效的。这表明它们可以作为不能达到目标水平或未来心血管事件高风险个体的附加治疗。泰国CV风险评分因其对泰国人群的特异性而被推荐。结论:2024年更新的临床实践指南为成人血脂异常的当代管理建立了一个框架,提供了建议,并作为一个综合资源,目标是在泰国预防ASCVD。
{"title":"2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention.","authors":"Praween Lolekha, Weerapan Khovidhunkit, Chaicharn Deerochanawong, Nuntakorn Thongtang, Thananya Boonyasirinant, Chatchalit Rattarasarn, Aurauma Chutinet, Vuddhidej Ophascharoensuk, Nicha Somlaw, Surapun Sitthisook, Surajit Suntorntham, Wannee Nitiyanant, Rungroj Krittayaphong","doi":"10.2478/abm-2024-0033","DOIUrl":"10.2478/abm-2024-0033","url":null,"abstract":"<p><strong>Background: </strong>The Royal College of Physicians of Thailand (RCPT) published a Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for Atherosclerotic Cardiovascular Disease (ASCVD) Prevention in 2016. The availability of newer classes of medications for dyslipidemia, supported by extensive clinical research findings, indicates a significant need for the updating of the existing clinical practice guideline.</p><p><strong>Objectives: </strong>To serve as guidelines on the management of dyslipidemia for Thai adults.</p><p><strong>Methods: </strong>The RCPT Dyslipidemia Guidelines Committee was established with representatives from selected professional societies to revise the 2016 Guideline by critically reviewing the latest evidence. Meetings were conducted from August to December 2023, culminating in a public hearing that engaged various stakeholders in January 2024. The final Thai version received approval in April 2024, while the English translation was completed in October 2024.</p><p><strong>Results: </strong>Lifestyle modifications and statins remain the cornerstone of therapy for dyslipidemia in adults across various clinical settings. Emerging evidence regarding newer classes of lipid-lowering medications indicates that these treatments are effective in lowering LDL-cholesterol levels and reducing atherosclerotic cardiovascular events. This suggests that they may serve as an add-on therapy for individuals who cannot achieve target levels or who are at high risk for future cardiovascular events. The Thai CV Risk Score is recommended due to its specificity for the Thai population.</p><p><strong>Conclusions: </strong>The 2024 updated clinical practice guidelines establish a framework, provide recommendations, and serve as a comprehensive resource for the contemporary management of dyslipidemia in adults, with the goal of preventing ASCVD in Thailand.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"246-267"},"PeriodicalIF":0.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of radiofrequency ablation for secondary hyperparathyroidism: a systematic review and meta-analysis. 射频消融治疗继发性甲状旁腺功能亢进的疗效和安全性:一项系统综述和荟萃分析。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.2478/abm-2024-0036
Mengyuan Li, Hongwei Jiang, Yunchang Wang, Fujun Li

Background: Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) that affects approximately 90% of end-stage renal disease and poses a significant threat to long-term survival and quality of life in patients.

Objectives: To assess whether radiofrequency ablation (RFA) is a productive and low-risk treatment for hyperparathyroidism secondary to CKD.

Methods: Embase, Web of Science, Cochrane Library, and PubMed were searched independently by two authors. The results after RFA and baseline biochemical indicators were compared, and parathyroid hormone (PTH), serum calcium, and serum phosphorus levels were the major outcomes.

Results: Four retrospective studies were screened out from 147 original literature and involved 118 cases. After RFA, serum PTH levels (1 d standardized mean difference [SMD] = -2.30, 95% confidence interval [CI] = from -3.04 to -1.56, P < 0.0001; 6 months SMD = -2.15, 95% CI = from -3.04 to -1.26, P < 0.0001; 12 months SMD = -2.35, 95% CI = from -3.52 to -1.17, P < 0.0001), serum calcium levels (1 d SMD = -1.49, 95% CI = from -2.18 to -0.81, P = 0.0001; 6 months SMD = -1.09, 95% CI = from -1.51 to -0.68, P < 0.0001), and serum phosphorus levels (1 d SMD = -1.37, 95% CI = from -1.67 to -1.07, P < 0.0001; 6 months SMD = -1.06, 95% CI = from -1.35 to -0.78, P < 0.0001) decreased significantly.

Conclusions: RFA, the newest thermal ablation technique, can effectively and safely treat hyperparathyroidism secondary to CKD. Hoarseness is the most common complication but is reversed within 6 months.

背景:继发性甲状旁腺功能亢进(SHPT)是慢性肾脏疾病(CKD)的常见并发症,影响约90%的终末期肾脏疾病,对患者的长期生存和生活质量构成重大威胁。目的:评估射频消融(RFA)是否是慢性肾病继发甲状旁腺功能亢进的有效和低风险治疗方法。方法:由两位作者独立检索Embase、Web of Science、Cochrane Library和PubMed。将RFA后的结果与基线生化指标进行比较,以甲状旁腺激素(PTH)、血清钙、血清磷水平为主要指标。结果:从147篇原始文献中筛选出4篇回顾性研究,涉及118例病例。RFA后血清PTH水平(1 d标准化平均差[SMD] = -2.30, 95%可信区间[CI] = -3.04 ~ -1.56, P < 0.0001;6个月SMD = -2.15, 95% CI = -3.04 ~ -1.26, P < 0.0001;12个月SMD = -2.35, 95% CI = -3.52 ~ -1.17, P < 0.0001),血清钙水平(1天SMD = -1.49, 95% CI = -2.18 ~ -0.81, P = 0.0001;6个月SMD = -1.09, 95% CI = -1.51 ~ -0.68, P < 0.0001),血清磷水平(1天SMD = -1.37, 95% CI = -1.67 ~ -1.07, P < 0.0001;6个月SMD = -1.06, 95% CI = -1.35 ~ -0.78, P < 0.0001)显著下降。结论:RFA是一种最新的热消融技术,可安全有效地治疗CKD继发性甲状旁腺功能亢进。声音嘶哑是最常见的并发症,但在6个月内就会好转。
{"title":"Efficacy and safety of radiofrequency ablation for secondary hyperparathyroidism: a systematic review and meta-analysis.","authors":"Mengyuan Li, Hongwei Jiang, Yunchang Wang, Fujun Li","doi":"10.2478/abm-2024-0036","DOIUrl":"10.2478/abm-2024-0036","url":null,"abstract":"<p><strong>Background: </strong>Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) that affects approximately 90% of end-stage renal disease and poses a significant threat to long-term survival and quality of life in patients.</p><p><strong>Objectives: </strong>To assess whether radiofrequency ablation (RFA) is a productive and low-risk treatment for hyperparathyroidism secondary to CKD.</p><p><strong>Methods: </strong>Embase, Web of Science, Cochrane Library, and PubMed were searched independently by two authors. The results after RFA and baseline biochemical indicators were compared, and parathyroid hormone (PTH), serum calcium, and serum phosphorus levels were the major outcomes.</p><p><strong>Results: </strong>Four retrospective studies were screened out from 147 original literature and involved 118 cases. After RFA, serum PTH levels (1 d standardized mean difference [SMD] = -2.30, 95% confidence interval [CI] = from -3.04 to -1.56, <i>P</i> < 0.0001; 6 months SMD = -2.15, 95% CI = from -3.04 to -1.26, <i>P</i> < 0.0001; 12 months SMD = -2.35, 95% CI = from -3.52 to -1.17, <i>P</i> < 0.0001), serum calcium levels (1 d SMD = -1.49, 95% CI = from -2.18 to -0.81, <i>P</i> = 0.0001; 6 months SMD = -1.09, 95% CI = from -1.51 to -0.68, <i>P</i> < 0.0001), and serum phosphorus levels (1 d SMD = -1.37, 95% CI = from -1.67 to -1.07, <i>P</i> < 0.0001; 6 months SMD = -1.06, 95% CI = from -1.35 to -0.78, <i>P</i> < 0.0001) decreased significantly.</p><p><strong>Conclusions: </strong>RFA, the newest thermal ablation technique, can effectively and safely treat hyperparathyroidism secondary to CKD. Hoarseness is the most common complication but is reversed within 6 months.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"287-296"},"PeriodicalIF":0.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of blood thiosulfate produced by postmortem changes for the diagnosis of hydrogen sulfide poisoning in forensic autopsy. 死后血液硫代硫酸盐变化对法医尸检诊断硫化氢中毒的影响。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.2478/abm-2024-0035
Masaaki Suzuka, Shigeki Jin, Akiko Takeuchi, Manabu Murakami, Keiko Takahashi, Kotaro Matoba

Background: Thiosulfate concentration in blood is an important indicator for the diagnosis of hydrogen sulfide poisoning. It may also be detected at high levels in postmortem decomposition cases.

Objectives: To determine the effect of postmortem decomposition on blood thiosulfate concentration and define precautions for diagnosing hydrogen sulfide poisoning based on thiosulfate concentration.

Methods: A total of 57 cadavers (37 males and 20 females) of non-hydrogen sulfide poisoning-related deaths that underwent forensic autopsy in our department between 2016 and 2019 were classified into the non-decomposed (19 cases), partially decomposed (19 cases), and severely decomposed (19 cases) groups based on forensic findings. Blood samples collected from each case were analyzed for thiosulfate concentration using liquid chromatography-tandem mass spectrometry.

Results: The mean concentration of thiosulfate detected in the blood was 70.9 (10.5-266.6) μmol/L in the severely decomposed group, 16.3 (0.1-52.7) μmol/L in the partially decomposed group, and 1.1 (0.1-3.6) μmol/L in the non-decomposed group. There was a statistically significant difference between each of the 3 groups (P < 0.01).

Conclusions: Previous studies have reported a blood thiosulfate concentration of >14 μmol/L in hydrogen sulfide poisoning cases and <4 μmol/L in normal cases. Thus, thiosulfate concentration is believed to have a significant impact on the diagnosis of hydrogen sulfide poisoning. This study revealed that postmortem decomposition produced thiosulfate in the blood, and the concentration of thiosulfate was often as high as that observed in cases of hydrogen sulfide poisoning-related death. In addition to cases of advanced decomposition, an increase in thiosulfate concentration was also observed in cases of partial decomposition. Therefore, when measuring thiosulfate concentration as an indicator of hydrogen sulfide poisoning, it is necessary to carefully consider the influence of decomposition.

背景:血中硫代硫酸盐浓度是诊断硫化氢中毒的重要指标。在尸体腐烂的情况下也可能检测到高水平。目的:探讨尸体腐解对血液硫代硫酸盐浓度的影响,确定基于硫代硫酸盐浓度诊断硫化氢中毒的注意事项。方法:2016 - 2019年在我科进行法医尸检的非硫化氢中毒死亡尸体57具(男37例,女20例),根据法医鉴定结果分为未腐烂组(19例)、部分腐烂组(19例)和严重腐烂组(19例)。采用液相色谱-串联质谱法对每个病例的血液样本进行硫代硫酸盐浓度分析。结果:严重分解组血硫代硫酸盐平均浓度为70.9 (10.5 ~ 266.6)μmol/L,部分分解组血硫代硫酸盐平均浓度为16.3 (0.1 ~ 52.7)μmol/L,未分解组血硫代硫酸盐平均浓度为1.1 (0.1 ~ 3.6)μmol/L。3组间比较差异均有统计学意义(P < 0.01)。结论:既往研究报道了硫化氢中毒患者血硫代硫酸盐浓度为bbb14 μmol/L
{"title":"Influence of blood thiosulfate produced by postmortem changes for the diagnosis of hydrogen sulfide poisoning in forensic autopsy.","authors":"Masaaki Suzuka, Shigeki Jin, Akiko Takeuchi, Manabu Murakami, Keiko Takahashi, Kotaro Matoba","doi":"10.2478/abm-2024-0035","DOIUrl":"10.2478/abm-2024-0035","url":null,"abstract":"<p><strong>Background: </strong>Thiosulfate concentration in blood is an important indicator for the diagnosis of hydrogen sulfide poisoning. It may also be detected at high levels in postmortem decomposition cases.</p><p><strong>Objectives: </strong>To determine the effect of postmortem decomposition on blood thiosulfate concentration and define precautions for diagnosing hydrogen sulfide poisoning based on thiosulfate concentration.</p><p><strong>Methods: </strong>A total of 57 cadavers (37 males and 20 females) of non-hydrogen sulfide poisoning-related deaths that underwent forensic autopsy in our department between 2016 and 2019 were classified into the non-decomposed (19 cases), partially decomposed (19 cases), and severely decomposed (19 cases) groups based on forensic findings. Blood samples collected from each case were analyzed for thiosulfate concentration using liquid chromatography-tandem mass spectrometry.</p><p><strong>Results: </strong>The mean concentration of thiosulfate detected in the blood was 70.9 (10.5-266.6) μmol/L in the severely decomposed group, 16.3 (0.1-52.7) μmol/L in the partially decomposed group, and 1.1 (0.1-3.6) μmol/L in the non-decomposed group. There was a statistically significant difference between each of the 3 groups (<i>P</i> < 0.01).</p><p><strong>Conclusions: </strong>Previous studies have reported a blood thiosulfate concentration of >14 μmol/L in hydrogen sulfide poisoning cases and <4 μmol/L in normal cases. Thus, thiosulfate concentration is believed to have a significant impact on the diagnosis of hydrogen sulfide poisoning. This study revealed that postmortem decomposition produced thiosulfate in the blood, and the concentration of thiosulfate was often as high as that observed in cases of hydrogen sulfide poisoning-related death. In addition to cases of advanced decomposition, an increase in thiosulfate concentration was also observed in cases of partial decomposition. Therefore, when measuring thiosulfate concentration as an indicator of hydrogen sulfide poisoning, it is necessary to carefully consider the influence of decomposition.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"281-286"},"PeriodicalIF":0.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and associated factors of dysphonia in non-hospitalized Thai COVID-19 patients: a descriptive study with Thai-VHI10 Assessment. 泰国非住院COVID-19患者的发声障碍患病率及相关因素:一项泰国vhi10评估的描述性研究
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.2478/abm-2024-0037
Thitaree Suwannutsiri, Peerada Arreenich, Premsuda Sombuntham

Background: The COVID-19 pandemic first emerged in December 2019 and rapidly spread globally, including Thailand. While respiratory symptoms remain the primary manifestation of the disease, upper respiratory tract symptoms, including dysphonia, have been reported in various studies.

Objectives: To determine the prevalence of dysphonia in non-hospitalized Thai COVID-19 patients and identify associated factors using the Thai-Voice Handicap Index-10.

Methods: This study investigates the prevalence of dysphonia and associated factors in non-hospitalized Thai COVID-19 patients. Conducted from September 2022 to February 2023, it enrolled healthcare workers who tested positive for COVID-19 but were not hospitalized.

Results: Among 82 patients, 53 (64.6%) reported dysphonia, which was significantly associated with cough (P = 0.013) and nasal discharge (P = 0.047). Substantial improvement was observed at the 3-month follow-up (73.6%). Vaccination may serve as a protective factor (crude odds ratio < 1).

Conclusion: The prevalence of dysphonia among non-hospitalized COVID-19 patients in Thailand is 63.6%, linked to cough and nasal congestion, with symptoms likely to subside within 3 months.

背景:2019年12月首次出现COVID-19大流行,并迅速在全球蔓延,包括泰国。虽然呼吸道症状仍然是该病的主要表现,但在各种研究中也报道了上呼吸道症状,包括发音困难。目的:利用泰语语音障碍指数-10确定未住院的泰国COVID-19患者中语音障碍的患病率,并确定相关因素。方法:本研究调查泰国非住院COVID-19患者的发声障碍患病率及相关因素。该研究于2022年9月至2023年2月进行,招募了COVID-19检测呈阳性但未住院的医护人员。结果:82例患者中,有53例(64.6%)出现发声障碍,且与咳嗽(P = 0.013)和流鼻液(P = 0.047)显著相关。在3个月的随访中观察到实质性改善(73.6%)。疫苗接种可能是保护因素(粗优势比< 1)。结论:泰国非住院COVID-19患者的发声障碍患病率为63.6%,与咳嗽和鼻塞有关,症状可能在3个月内消退。
{"title":"Prevalence and associated factors of dysphonia in non-hospitalized Thai COVID-19 patients: a descriptive study with Thai-VHI10 Assessment.","authors":"Thitaree Suwannutsiri, Peerada Arreenich, Premsuda Sombuntham","doi":"10.2478/abm-2024-0037","DOIUrl":"10.2478/abm-2024-0037","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic first emerged in December 2019 and rapidly spread globally, including Thailand. While respiratory symptoms remain the primary manifestation of the disease, upper respiratory tract symptoms, including dysphonia, have been reported in various studies.</p><p><strong>Objectives: </strong>To determine the prevalence of dysphonia in non-hospitalized Thai COVID-19 patients and identify associated factors using the Thai-Voice Handicap Index-10.</p><p><strong>Methods: </strong>This study investigates the prevalence of dysphonia and associated factors in non-hospitalized Thai COVID-19 patients. Conducted from September 2022 to February 2023, it enrolled healthcare workers who tested positive for COVID-19 but were not hospitalized.</p><p><strong>Results: </strong>Among 82 patients, 53 (64.6%) reported dysphonia, which was significantly associated with cough (<i>P</i> = 0.013) and nasal discharge (<i>P</i> = 0.047). Substantial improvement was observed at the 3-month follow-up (73.6%). Vaccination may serve as a protective factor (crude odds ratio < 1).</p><p><strong>Conclusion: </strong>The prevalence of dysphonia among non-hospitalized COVID-19 patients in Thailand is 63.6%, linked to cough and nasal congestion, with symptoms likely to subside within 3 months.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"297-302"},"PeriodicalIF":0.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prospective pilot study of kidney-specific biomarkers to detect acute kidney injury after cytoreduction and hyperthermic intraperitoneal chemotherapy. 肾特异性生物标志物检测细胞减少和腹腔内高温化疗后急性肾损伤的前瞻性先导研究。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.2478/abm-2024-0034
Chao-Yu Chen, Ting-Yao Wang, Hung-Yu Chang, Min-Chi Chen, Lan-Yan Yang

Background: Acute kidney injury (AKI) is a critical morbidity after cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Objective: This study was conducted to investigate the use of kidney-specific biomarkers to evaluate the diagnostic accuracy of post-HIPEC AKI.

Methods: Patients who received CRS/HIPEC were prospectively enrolled in this study. We serially sampled urine neutrophil gelatinase-associated lipocalin (NGAL), serum cystatin C (sCyC), and β2 microglobulin (sβ2-MG) on the day before CRS/HIPEC and then 2 h, 1 d, 2 d, 3 d, and 7 d after CRS/HIPEC. The primary outcome was the occurrence of AKI during the first 7 d. The areas under the receiver operating characteristic curve (AUCs) were calculated to evaluate the detection performance.

Results: A total of 75 patients were eligible, of whom 5 (6.7%) fulfilled the criteria of AKI during the study period (AKI group) and 70 did not (non-AKI group). No significant differences were observed in these biomarkers between the two groups, except for sβ2-MG on day 3 (P = 0.025). Regarding changes in biomarker concentrations, the AKI group had a significantly higher concentration range of sCyC on day 3 (P = 0.009) and sβ2-MG on day 1 and day 3 (P = 0.013 and 0.019).

Conclusions: This is the first prospective study to evaluate the value of kidney-specific biomarkers in patients after CRS/HIPEC. We found that AKI cannot be predicted by simply using the absolute measurements of these biomarkers because of the heterogeneous characteristics of the patients.

背景:急性肾损伤(AKI)是细胞减少和腹腔内高热化疗(CRS/HIPEC)后的一种严重并发症。目的:本研究旨在探讨使用肾脏特异性生物标志物来评估hipec后AKI的诊断准确性。方法:前瞻性纳入接受CRS/HIPEC治疗的患者。我们在CRS/HIPEC前一天和CRS/HIPEC后2小时、1天、2天、3天和7天连续取样尿中性粒细胞明胶酶相关脂钙蛋白(NGAL)、血清胱抑素C (sCyC)和β2微球蛋白(sβ2-MG)。主要终点是前7天内AKI的发生情况。计算受试者工作特征曲线(auc)下的面积以评估检测性能。结果:共有75例患者入选,其中5例(6.7%)在研究期间达到AKI标准(AKI组),70例(非AKI组)未达到AKI标准。除第3天的sβ2-MG外,两组间这些生物标志物均无显著差异(P = 0.025)。在生物标志物浓度变化方面,AKI组在第3天sCyC (P = 0.009)和sβ2-MG在第1天和第3天的浓度范围显著升高(P = 0.013和0.019)。结论:这是第一个评估CRS/HIPEC患者肾脏特异性生物标志物价值的前瞻性研究。我们发现,由于患者的异质性特征,不能通过简单地使用这些生物标志物的绝对测量来预测AKI。
{"title":"A prospective pilot study of kidney-specific biomarkers to detect acute kidney injury after cytoreduction and hyperthermic intraperitoneal chemotherapy.","authors":"Chao-Yu Chen, Ting-Yao Wang, Hung-Yu Chang, Min-Chi Chen, Lan-Yan Yang","doi":"10.2478/abm-2024-0034","DOIUrl":"10.2478/abm-2024-0034","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is a critical morbidity after cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).</p><p><strong>Objective: </strong>This study was conducted to investigate the use of kidney-specific biomarkers to evaluate the diagnostic accuracy of post-HIPEC AKI.</p><p><strong>Methods: </strong>Patients who received CRS/HIPEC were prospectively enrolled in this study. We serially sampled urine neutrophil gelatinase-associated lipocalin (NGAL), serum cystatin C (sCyC), and β2 microglobulin (sβ2-MG) on the day before CRS/HIPEC and then 2 h, 1 d, 2 d, 3 d, and 7 d after CRS/HIPEC. The primary outcome was the occurrence of AKI during the first 7 d. The areas under the receiver operating characteristic curve (AUCs) were calculated to evaluate the detection performance.</p><p><strong>Results: </strong>A total of 75 patients were eligible, of whom 5 (6.7%) fulfilled the criteria of AKI during the study period (AKI group) and 70 did not (non-AKI group). No significant differences were observed in these biomarkers between the two groups, except for sβ2-MG on day 3 (<i>P</i> = 0.025). Regarding changes in biomarker concentrations, the AKI group had a significantly higher concentration range of sCyC on day 3 (<i>P</i> = 0.009) and sβ2-MG on day 1 and day 3 (<i>P</i> = 0.013 and 0.019).</p><p><strong>Conclusions: </strong>This is the first prospective study to evaluate the value of kidney-specific biomarkers in patients after CRS/HIPEC. We found that AKI cannot be predicted by simply using the absolute measurements of these biomarkers because of the heterogeneous characteristics of the patients.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"268-280"},"PeriodicalIF":0.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy and the value of markers for acute kidney injury. 细胞减缩术±腹腔热化疗与急性肾损伤标志物的价值。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.2478/abm-2024-0032
{"title":"Cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy and the value of markers for acute kidney injury.","authors":"","doi":"10.2478/abm-2024-0032","DOIUrl":"10.2478/abm-2024-0032","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 6","pages":"244-245"},"PeriodicalIF":0.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A preliminary study of primary retroperitoneal sarcoma at a tertiary University Hospital in Bangkok, Thailand: a retrospective observational study. 泰国曼谷一家三级甲等大学医院对原发性腹膜后肉瘤的初步研究:一项回顾性观察研究。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-31 eCollection Date: 2024-10-01 DOI: 10.2478/abm-2024-0031
Suvit Sriussadaporn, Sukanya Sriussadaporn, Rattaplee Pak-Art, Kritaya Kritayakirana, Supparerk Prichayudh, Pasurachate Samorn, Natawat Narueponjirakul, Punthita Aimsupanimitr, Apinan Uthaipaisanwong

Background: Retroperitoneal sarcoma (RPS) is rare and difficult to treat with a high recurrent rate. Very little data regarding primary RPS exists in Thailand.

Objectives: To study the outcome of treatment of primary RPS at a tertiary University Hospital in Bangkok, Thailand.

Methods: All patients who had RPS undergoing the first surgical resection at King Chulalongkorn Memorial Hospital from June 2003 to December 2019 were retrospectively enrolled in the study. Perioperative management, results of treatment, postoperative complications, and outcome were analyzed.

Results: Thirty-eight patients entered the study. Large abdominal mass was the most common presentation (90%). Liposarcoma was the most common histology (58%). Twenty patients (53%) had preoperative core needle biopsy and 21 (55%) underwent preoperative radiotherapy (RT). The tumor size ranged from 3 cm to 48 cm (median 22 cm). Five patients (13%) had total mass removal only while 33 (87%) had complete gross resection with ≥1 visceral organ resection. Surgical margins classified as R0, R1, and R2 were 61%, 34%, and 5%, respectively. Five patients (16%) had postoperative complications. There was no 30-day postoperative mortality. The local recurrence rate was 34%. Survival analysis revealed a 5-year overall survival rate of 37% and 5-year disease-free survival rate of 29%. The 5-year and 10-year recurrent rates were 71% and 95%, respectively. Multivariate analysis showed that preoperative radiation was the only factor reducing recurrence (19% vs. 53%, OR: 0.21, P = 0.011).

Conclusion: The preliminary study of outcome of the treatment of primary RPS at our institution showed a fair prognosis of this rare malignancy despite our aggressive surgical approaches. Preoperative radiation may help reduce recurrence in selected primary RPS patients.

背景:腹膜后肉瘤(RPS腹膜后肉瘤(RPS)非常罕见,治疗难度大,复发率高。泰国有关原发性腹膜后肉瘤的数据很少:研究泰国曼谷一家三级大学医院治疗原发性 RPS 的结果:方法:回顾性纳入2003年6月至2019年12月在朱拉隆功国王纪念医院接受首次手术切除的所有RPS患者。对围手术期管理、治疗结果、术后并发症和预后进行了分析:38名患者参与了研究。腹部大肿块是最常见的表现(90%)。脂肪肉瘤是最常见的组织学类型(58%)。20名患者(53%)在术前进行了核心针活检,21名患者(55%)在术前接受了放射治疗(RT)。肿瘤大小从3厘米到48厘米不等(中位数为22厘米)。5名患者(13%)只进行了全部肿块切除,33名患者(87%)进行了完全的大体切除,并切除了≥1个内脏器官。手术切缘分为R0、R1和R2的比例分别为61%、34%和5%。五名患者(16%)出现术后并发症。术后30天无死亡病例。局部复发率为34%。生存分析显示,5年总生存率为37%,5年无病生存率为29%。5年和10年复发率分别为71%和95%。多变量分析显示,术前放疗是降低复发率的唯一因素(19% 对 53%,OR:0.21,P = 0.011):我院对原发性RPS治疗效果的初步研究表明,尽管我们采取了积极的手术方法,但这种罕见恶性肿瘤的预后尚可。术前放疗可能有助于减少部分原发性RPS患者的复发。
{"title":"A preliminary study of primary retroperitoneal sarcoma at a tertiary University Hospital in Bangkok, Thailand: a retrospective observational study.","authors":"Suvit Sriussadaporn, Sukanya Sriussadaporn, Rattaplee Pak-Art, Kritaya Kritayakirana, Supparerk Prichayudh, Pasurachate Samorn, Natawat Narueponjirakul, Punthita Aimsupanimitr, Apinan Uthaipaisanwong","doi":"10.2478/abm-2024-0031","DOIUrl":"10.2478/abm-2024-0031","url":null,"abstract":"<p><strong>Background: </strong>Retroperitoneal sarcoma (RPS) is rare and difficult to treat with a high recurrent rate. Very little data regarding primary RPS exists in Thailand.</p><p><strong>Objectives: </strong>To study the outcome of treatment of primary RPS at a tertiary University Hospital in Bangkok, Thailand.</p><p><strong>Methods: </strong>All patients who had RPS undergoing the first surgical resection at King Chulalongkorn Memorial Hospital from June 2003 to December 2019 were retrospectively enrolled in the study. Perioperative management, results of treatment, postoperative complications, and outcome were analyzed.</p><p><strong>Results: </strong>Thirty-eight patients entered the study. Large abdominal mass was the most common presentation (90%). Liposarcoma was the most common histology (58%). Twenty patients (53%) had preoperative core needle biopsy and 21 (55%) underwent preoperative radiotherapy (RT). The tumor size ranged from 3 cm to 48 cm (median 22 cm). Five patients (13%) had total mass removal only while 33 (87%) had complete gross resection with ≥1 visceral organ resection. Surgical margins classified as R0, R1, and R2 were 61%, 34%, and 5%, respectively. Five patients (16%) had postoperative complications. There was no 30-day postoperative mortality. The local recurrence rate was 34%. Survival analysis revealed a 5-year overall survival rate of 37% and 5-year disease-free survival rate of 29%. The 5-year and 10-year recurrent rates were 71% and 95%, respectively. Multivariate analysis showed that preoperative radiation was the only factor reducing recurrence (19% vs. 53%, OR: 0.21, <i>P</i> = 0.011).</p><p><strong>Conclusion: </strong>The preliminary study of outcome of the treatment of primary RPS at our institution showed a fair prognosis of this rare malignancy despite our aggressive surgical approaches. Preoperative radiation may help reduce recurrence in selected primary RPS patients.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 5","pages":"236-243"},"PeriodicalIF":0.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventive effects of coixol, an active compound of adlay seed, in NGF-differentiated PC12 cells against beta-amyloid25-35-induced neurotoxicity. 薏苡仁活性化合物薏苡仁醇对 NGF 分化 PC12 细胞中 beta-amyloid25-35 诱导的神经毒性的预防作用。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-31 eCollection Date: 2024-10-01 DOI: 10.2478/abm-2024-0030
Jan-Yow Chen, Chien-Yu Li, Mei-Chin Mong, Mei-Chin Yin

Background: The health benefits of coixol, an active compound of adlay seed, have attracted certain attention. Adlay seed is often adopted in traditional Chinese medicine for the treatment of various inflammatory disorders. Thus, it is hypothesized that coixol could protect neuronal cells.

Objectives: The preventive effects of coixol against Abeta25-35-induced damage in nerve growth factor-differentiated PC12 cells were explored.

Methods: Differentiated PC12 cells were treated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, and 2 μM for 48 h. Then, cells were further exposed to Abeta25-35 at 20 μM for 24 h.

Results: Coixol treatments at 0.25-2 μM exhibited antiapoptotic effect via increasing Bcl-2 mRNA expression, mitochondrial membrane potential, and Na+-K+ ATPase activity as well as decreasing Bax mRNA expression, caspase-3 activity, and intracellular Ca2+ release. In addition, coixol treatments at 0.25-2 μM alleviated oxidative and inflammatory responses via lowering reactive oxygen species level, increasing glutathione content, promoting the activity of glutathione peroxidase, glutathione reductase, and catalase, decreasing the generation of tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and prostaglandin E2. Furthermore, coixol treatments at 0.25-2 μM diminished intracellular Ca2+ release, and restricted nuclear factor kappa B-binding activity and phosphorylation of p65 and p38. Coixol treatments at 0.5-2 μM increased protein generation of nuclear factor E2-related factor 2, and limited protein production of inducible nitric oxide synthase and receptor of advanced glycation end product.

Conclusion: Our novel findings suggested that coixol was a compelling agent against beta-amyloid peptide-induced neurotoxicity.

背景:薏苡仁的活性化合物薏苡仁醇对健康的益处引起了人们的关注。薏苡仁常被用于治疗各种炎症性疾病。因此,人们推测薏苡仁醇可以保护神经细胞:目的:探讨薏苡仁酚对神经生长因子分化的 PC12 细胞中 Abeta25-35 诱导的损伤的预防作用:用0.125 μM、0.25 μM、0.5 μM、1 μM和2 μM的coixol处理分化PC12细胞48小时:结果:0.25-2 μM浓度的薏苡仁酚能提高Bcl-2 mRNA表达、线粒体膜电位和Na+-K+ ATP酶活性,降低Bax mRNA表达、caspase-3活性和细胞内Ca2+释放,从而起到抗凋亡作用。此外,0.25-2 μM浓度的薏苡仁酚还能降低活性氧水平,增加谷胱甘肽含量,促进谷胱甘肽过氧化物酶、谷胱甘肽还原酶和过氧化氢酶的活性,减少肿瘤坏死因子-α、白细胞介素(IL)-1β、IL-6和前列腺素E2的生成,从而减轻氧化和炎症反应。此外,0.25-2 μM 的 Coixol 处理可减少细胞内 Ca2+ 的释放,限制核因子卡巴 B 结合活性以及 p65 和 p38 的磷酸化。0.5-2 μM浓度的薏苡仁酚能增加核因子E2相关因子2的蛋白生成,限制诱导型一氧化氮合酶和高级糖化终产物受体的蛋白生成:我们的新发现表明,薏苡仁酚是抗β-淀粉样肽诱导的神经毒性的有效药物。
{"title":"Preventive effects of coixol, an active compound of adlay seed, in NGF-differentiated PC12 cells against beta-amyloid<sub>25-35</sub>-induced neurotoxicity.","authors":"Jan-Yow Chen, Chien-Yu Li, Mei-Chin Mong, Mei-Chin Yin","doi":"10.2478/abm-2024-0030","DOIUrl":"10.2478/abm-2024-0030","url":null,"abstract":"<p><strong>Background: </strong>The health benefits of coixol, an active compound of adlay seed, have attracted certain attention. Adlay seed is often adopted in traditional Chinese medicine for the treatment of various inflammatory disorders. Thus, it is hypothesized that coixol could protect neuronal cells.</p><p><strong>Objectives: </strong>The preventive effects of coixol against Abeta<sub>25-35</sub>-induced damage in nerve growth factor-differentiated PC12 cells were explored.</p><p><strong>Methods: </strong>Differentiated PC12 cells were treated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, and 2 μM for 48 h. Then, cells were further exposed to Abeta<sub>25-35</sub> at 20 μM for 24 h.</p><p><strong>Results: </strong>Coixol treatments at 0.25-2 μM exhibited antiapoptotic effect via increasing Bcl-2 mRNA expression, mitochondrial membrane potential, and Na<sup>+</sup>-K<sup>+</sup> ATPase activity as well as decreasing Bax mRNA expression, caspase-3 activity, and intracellular Ca<sup>2+</sup> release. In addition, coixol treatments at 0.25-2 μM alleviated oxidative and inflammatory responses via lowering reactive oxygen species level, increasing glutathione content, promoting the activity of glutathione peroxidase, glutathione reductase, and catalase, decreasing the generation of tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and prostaglandin E<sub>2</sub>. Furthermore, coixol treatments at 0.25-2 μM diminished intracellular Ca<sup>2+</sup> release, and restricted nuclear factor kappa B-binding activity and phosphorylation of p65 and p38. Coixol treatments at 0.5-2 μM increased protein generation of nuclear factor E2-related factor 2, and limited protein production of inducible nitric oxide synthase and receptor of advanced glycation end product.</p><p><strong>Conclusion: </strong>Our novel findings suggested that coixol was a compelling agent against beta-amyloid peptide-induced neurotoxicity.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 5","pages":"224-235"},"PeriodicalIF":0.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Support vector machine classification of patients with depression based on resting-state electroencephalography. 基于静息态脑电图的抑郁症患者支持向量机分类。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-31 eCollection Date: 2024-10-01 DOI: 10.2478/abm-2024-0029
Chia-Yen Yang, Yin-Zhen Chen

Background: Depression is one of the most common mental disorders. Although depression is typically diagnosed by identifying specific symptoms and through history, no recognized standard for depression diagnosis exists. This assures the development of objective diagnostic tools for depression.

Objectives: We investigated the differences in the resting-state electroencephalograms (EEGs) of patients with depression and healthy controls (HCs) to distinguish patients from HCs by using a support vector machine (SVM) classifier with the following two feature selection approaches: t test and receiver operating characteristic analysis.

Methods: We used the EEG data from the Patient Repository of EEG Data + Computational Tools; this study included 21 patients with depressive disorder (MDD) and 21 HCs. The relative frequency power, alpha interhemispheric asymmetry, left-right coherence, strength, clustering coefficient (CC), shortest path length, sample entropy (SampEn), multiscale entropy (MSE), and detrended fluctuation analysis (DFA) data were extracted to determine candidate EEG features associated with depression.

Results: With the t-test selection, the SVM classifier demonstrated the highest performance with the accuracy, sensitivity, and specificity of 96.66%, 95.93%, and 97.550% for the eye-open condition and 91.33%, 90.59%, and 91.81% for the eye-closed condition, respectively. For comparisons of features in the 2 selection approaches, the most influential features were relative frequency power and left-right coherence.

Conclusion: Using this information to distinguish patients with MDD from HC subjects with the SVM classifier resulted in a mean accuracy over 90%. Although this result may not be robust enough for clinical applications, further exploration is necessary given the simplicity, objectivity, and efficiency of the classifier.

背景介绍抑郁症是最常见的精神疾病之一。虽然抑郁症的诊断通常是通过识别特定症状和病史来进行的,但目前还没有公认的抑郁症诊断标准。这就需要开发客观的抑郁症诊断工具:我们研究了抑郁症患者和健康对照组(HCs)静息状态脑电图(EEGs)的差异,通过使用支持向量机(SVM)分类器和以下两种特征选择方法来区分抑郁症患者和健康对照组:t 检验和接受者操作特征分析:我们使用了 "患者脑电图数据存储库+计算工具 "中的脑电图数据;该研究包括 21 名抑郁障碍(MDD)患者和 21 名健康对照者。我们提取了相对频率功率、α半球间不对称性、左右相干性、强度、聚类系数(CC)、最短路径长度、样本熵(SampEn)、多尺度熵(MSE)和去趋势波动分析(DFA)数据,以确定与抑郁症相关的候选脑电图特征:在 t 检验选择中,SVM 分类器表现最佳,睁眼状态下的准确率、灵敏度和特异性分别为 96.66%、95.93% 和 97.550%,闭眼状态下的准确率、灵敏度和特异性分别为 91.33%、90.59% 和 91.81%。在两种选择方法的特征比较中,影响最大的特征是相对频率功率和左右一致性:结论:使用 SVM 分类器将 MDD 患者与 HC 受试者区分开来的平均准确率超过了 90%。尽管这一结果在临床应用中可能不够稳健,但考虑到分类器的简便性、客观性和高效性,进一步的探索还是很有必要的。
{"title":"Support vector machine classification of patients with depression based on resting-state electroencephalography.","authors":"Chia-Yen Yang, Yin-Zhen Chen","doi":"10.2478/abm-2024-0029","DOIUrl":"10.2478/abm-2024-0029","url":null,"abstract":"<p><strong>Background: </strong>Depression is one of the most common mental disorders. Although depression is typically diagnosed by identifying specific symptoms and through history, no recognized standard for depression diagnosis exists. This assures the development of objective diagnostic tools for depression.</p><p><strong>Objectives: </strong>We investigated the differences in the resting-state electroencephalograms (EEGs) of patients with depression and healthy controls (HCs) to distinguish patients from HCs by using a support vector machine (SVM) classifier with the following two feature selection approaches: t test and receiver operating characteristic analysis.</p><p><strong>Methods: </strong>We used the EEG data from the Patient Repository of EEG Data + Computational Tools; this study included 21 patients with depressive disorder (MDD) and 21 HCs. The relative frequency power, alpha interhemispheric asymmetry, left-right coherence, strength, clustering coefficient (CC), shortest path length, sample entropy (SampEn), multiscale entropy (MSE), and detrended fluctuation analysis (DFA) data were extracted to determine candidate EEG features associated with depression.</p><p><strong>Results: </strong>With the t-test selection, the SVM classifier demonstrated the highest performance with the accuracy, sensitivity, and specificity of 96.66%, 95.93%, and 97.550% for the eye-open condition and 91.33%, 90.59%, and 91.81% for the eye-closed condition, respectively. For comparisons of features in the 2 selection approaches, the most influential features were relative frequency power and left-right coherence.</p><p><strong>Conclusion: </strong>Using this information to distinguish patients with MDD from HC subjects with the SVM classifier resulted in a mean accuracy over 90%. Although this result may not be robust enough for clinical applications, further exploration is necessary given the simplicity, objectivity, and efficiency of the classifier.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 5","pages":"212-223"},"PeriodicalIF":0.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors of cholangiocarcinoma in areas not endemic for liver fluke infection. 肝吸虫感染非流行地区胆管癌的风险因素。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-31 eCollection Date: 2024-10-01 DOI: 10.2478/abm-2024-0028
Tongluk Teerasarntipan, Pawat Phuensan, Chonlada Phathong, Somchai Pinlaor, Parit Mekaroonkamol, Roongruedee Chaiteerakij

Background: Thailand has the world's highest prevalence of cholangiocarcinoma (CCA), especially in the endemic area of liver fluke Opisthorchis viverrini infection. However, other regions of Thailand still have relatively high CCA prevalence.

Objectives: We aimed to determine CCA risk factors in areas not endemic for OV infection.

Methods: A case--control study was performed at a referral center during December 2016-December 2017. We collected blood samples and information from CCA patients and identified them as cases. The control group comprised patients who visited a gastrointestinal clinic for colorectal cancer screening colonoscopy. Logistic regression analysis was used to determine risk factors for CCA.

Results: Of 138 participants, O. viverrini infection rate was higher in the case than in the control group (57.1% vs. 36.1%, P = 0.023). Male, O. viverrini infection, smoking, alcohol consumption, and biliary tract diseases were independent risk factors, whereas diabetes, obesity, and cirrhosis were not associated with CCA. By age and sex-adjusted analysis, chronic biliary tract diseases, especially choledochal cysts and smoking, were risk factors for CCA, with adjusted odds ratio (aOR) of 12.7 (95% confidence interval [CI]: 1.4-116.9) and 3.8 (95% CI: 1.3-11.8), respectively, while O. viverrini infection became insignificant risk for CCA (aOR 1.8, 95% CI: 0.8-4.1).

Conclusions: In contrast with endemic areas for O. viverrini infection, chronic biliary tract diseases and smoking are major risk factors, whereas O. viverrini infection has trivial contribution to the development of CCA.

背景:泰国是世界上胆管癌(CCA)发病率最高的国家,尤其是在肝吸虫感染流行区。然而,泰国其他地区的 CCA 发病率仍然相对较高:我们旨在确定非OV感染流行地区的CCA风险因素:方法:2016 年 12 月至 2017 年 12 月期间,我们在一家转诊中心开展了一项病例对照研究。我们收集了CCA患者的血样和信息,并将其确定为病例。对照组由到胃肠门诊进行结直肠癌筛查结肠镜检查的患者组成。采用逻辑回归分析确定CCA的风险因素:138名参与者中,病例组的O. viverrini感染率高于对照组(57.1% vs. 36.1%,P = 0.023)。男性、O. viverrini感染、吸烟、饮酒和胆道疾病是独立的风险因素,而糖尿病、肥胖和肝硬化与CCA无关。根据年龄和性别调整分析,慢性胆道疾病,尤其是胆总管囊肿和吸烟,是CCA的危险因素,调整后的几率比(aOR)分别为12.7(95% 置信区间[CI]:1.4-116.9)和3.8(95% CI:1.3-11.8),而O. viverrini感染成为CCA的微小危险因素(aOR 1.8,95% CI:0.8-4.1):结论:与O. viverrini感染流行地区相比,慢性胆道疾病和吸烟是CCA的主要风险因素,而O. viverrini感染对CCA的发病影响微乎其微。
{"title":"Risk factors of cholangiocarcinoma in areas not endemic for liver fluke infection.","authors":"Tongluk Teerasarntipan, Pawat Phuensan, Chonlada Phathong, Somchai Pinlaor, Parit Mekaroonkamol, Roongruedee Chaiteerakij","doi":"10.2478/abm-2024-0028","DOIUrl":"10.2478/abm-2024-0028","url":null,"abstract":"<p><strong>Background: </strong>Thailand has the world's highest prevalence of cholangiocarcinoma (CCA), especially in the endemic area of liver fluke <i>Opisthorchis viverrini</i> infection. However, other regions of Thailand still have relatively high CCA prevalence.</p><p><strong>Objectives: </strong>We aimed to determine CCA risk factors in areas not endemic for OV infection.</p><p><strong>Methods: </strong>A case--control study was performed at a referral center during December 2016-December 2017. We collected blood samples and information from CCA patients and identified them as cases. The control group comprised patients who visited a gastrointestinal clinic for colorectal cancer screening colonoscopy. Logistic regression analysis was used to determine risk factors for CCA.</p><p><strong>Results: </strong>Of 138 participants, <i>O. viverrini</i> infection rate was higher in the case than in the control group (57.1% vs. 36.1%, <i>P</i> = 0.023). Male, <i>O. viverrini</i> infection, smoking, alcohol consumption, and biliary tract diseases were independent risk factors, whereas diabetes, obesity, and cirrhosis were not associated with CCA. By age and sex-adjusted analysis, chronic biliary tract diseases, especially choledochal cysts and smoking, were risk factors for CCA, with adjusted odds ratio (aOR) of 12.7 (95% confidence interval [CI]: 1.4-116.9) and 3.8 (95% CI: 1.3-11.8), respectively, while <i>O. viverrini</i> infection became insignificant risk for CCA (aOR 1.8, 95% CI: 0.8-4.1).</p><p><strong>Conclusions: </strong>In contrast with endemic areas for <i>O. viverrini</i> infection, chronic biliary tract diseases and smoking are major risk factors, whereas <i>O. viverrini</i> infection has trivial contribution to the development of CCA.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 5","pages":"204-211"},"PeriodicalIF":0.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asian Biomedicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1